Develops portable hand-held breathalyzers. Manufactures fixed station breathalyzers. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 30% below its peak. The market has trimmed its expectations for the company.
Sales run at $9.0M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 14 buys and 6 sells. Management buying with its own money is usually read as a good sign.
A loss of $2.5M against $9.0M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.